



Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief Medical Officer

World Renowned Analgesic Researcher to Lead Drug Development Program

Charleston, South Carolina – August 1st 2007 – Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the appointment of Bernard Schachtel, M.D. as Chief Medical Officer. Dr. Schachtel is the President and Medical Director of Schachtel Research Company (SRC), a contract research organization in Jupiter, FL.

"It is an honor and a privilege to have Dr. Schachtel as Charleston's Chief Medical Officer" said Paul Bosse, Chief Executive Officer of Charleston. "I am excited to be working with one of the best analgesic researchers in this industry. He brings wide experience to Charleston Laboratories and has designed unique, executable, and comprehensive drug development programs for our various analgesic drugs. In addition, Charleston will benefit greatly from Dr. Schachtel's attention to detail, his scientific insights, and his expert management of clinical studies, which will help lead Charleston to the success he is accustomed to."



Dr. Schachtel brings to Charleston Laboratories over 30 years' experience in analgesic research. A former member of the Board of Directors of the American Society of Clinical Pharmacology and Therapeutics, Dr. Schachtel has also served as Consultant to the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.

Throughout his career Dr. Schachtel has also held academic appointments, including an Adjunct Professorship of Epidemiology and Biostatistics at McGill University and his current appointment at Yale University (Lecturer in Epidemiology and Public Health). He has also worked in the pharmaceutical industry (Procter & Gamble, Wyeth). Dr. Schachtel is currently located at SRC. All clinical studies for Charleston Laboratories will be overseen by SRC, known for its expertise in measuring patients' symptoms (such as pain, headache, heartburn, nausea and vomiting), and its participation in multiple drug approvals in the US and worldwide.



Dr. Schachtel received his undergraduate degree from Yale College, his medical degree from Columbia University, College of Physicians and Surgeons. After pediatric internship and residency at Yale and a two-year fellowship at the National Institutes of Health, he was a Robert Wood Johnson Clinical Scholar in the Departments of Medicine and Epidemiology and Public Health at the Yale University School of Medicine. His curriculum vitae cites over 150 publications, scientific presentations, and chapters in clinical pharmacology texts on different pain models, clinical trial methodology, and other issues of drug development.

Dr. Schachtel spoke of his attraction to Charleston Laboratories. "My career interest has been in critically evaluating medications that treat patients' symptoms. Because Charleston Laboratories is focused on developing analgesics that prevent or alleviate troublesome symptoms (such as nausea and vomiting) in patients who require opioid therapy, I am excited to head the Charleston Labs' clinical research program.

The drugs in Charleston's pipeline represent a meaningful contribution to the field of pain management," he said, "and a genuine patient benefit. It will be professionally rewarding to work with the energetic and talented team at Charleston and see these drugs reach the patients who need them."



About Charleston Laboratories, Inc.

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.

###